Welcome to BioSeeker Group!

Triple Analysis: Prostate Cancer, Antibodies and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4867
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Prostate Cancer, Antibodies and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two compound strategies of Antibodies and Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Antibodies and Peptides.

    To find out more about Triple Analysis: Prostate Cancer, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part II: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Affymax
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allos Therapeutics
Allostera
Allosterix
AlphaVax
Alseres Pharmaceuticals
ALSP
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Amorfix Life Sciences
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardana
Areva
arGEN-X
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Berkeley Lab
Biocon
Bioenvision
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
BioMarin
BioNetWorks
BioSante
Biosceptre
Biostar
Biotecnol
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Circadian Technologies
Cleveland BioLabs
Clinuvel
Colby
Compugen
Cosmo Bioscience
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Debiopharm
Dendreon
DiaMedica
Digna Biotech
Dompe
Dongkook Pharm
Dr Reddy’s
Dyax
ECI
Eisai
Elan
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
EpiCept
Ergon Pharmaceuticals
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
Ferring
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gemin X Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GENova Biotherapeutics
Genovax
GenPat77
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
IDM Pharma
IGF Oncology
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Karo Bio
Karyon-CTT
Kinex
Kirax
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
MolMed
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
Neurobiological Technologies
Neurocrine Biosciences
Nidus Laboratories
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protagonist
Q Chip
QLT
Ramot
Raptor Pharmaceutical
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Rexahn
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shire
Siena Biotech
Soligenix
Sophiris Bio
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
Sunol Molecular
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Titan Pharmaceuticals
Tokai Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
Velacor Therapeutics
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
XBiotech
Xencor
Xerion
Xigen
Xoma
Y’s Therapeutics
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEZS-108
afamelanotide
afatinib
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
ALT-801
alvocidib
amatuximab
AME-133
AMG-386
amonafide dihydrochloride
amonafide malate
angiopep+paclitaxel
APC-100
APR-246
ARC-100
atrasentan
AV-299
AVX-701
bafetinib
belimumab
bevacizumab
BHQ880
BIBF-1120
bicalutamide
blinatumomab
BMS-663513
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brentuximab vedotin
BT-062
buserelin
Cabozantinib
carlumab
catumaxomab
CBP-501
CDX-1307
CDX-1401
cediranib
celecoxib
cetuximab
cixutumumab
CMAB302
CMAB304
conatumumab
corticorelin acetate
CT-011
custirsen
dalotuzumab
danusertib
daratumumab
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
elotuzumab
EMD-273063
EMD525797
emepepimut-S
entinostat
enzastaurin hydrochloride
EP-100
epratuzumab
epratuzumab-Y90
ertumaxomab
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
farletuzumab
figitumumab
flutamide
FPI-01
fresolimumab
fulvestrant
galiximab
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
goserelin
GS-6634
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
histrelin
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imMucin
inecalcitol
inotuzumab ozogamicin
INSM-18
interleukins
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
irosustat
ISA-P53-01
ispinesib mesylate
kahalalide F
KX2-391
L19-TNFalpha
lanreotide
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
lintuzumab
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDV-3100
MDX-1379
MEDI-551
MEDI-573
milatuzumab
milatuzumab-doxorubicin
MLN-8237
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
Nab-docetaxel
nadroparin
NAFB001
naptumomab estafenatox
natalizumab
necitumumab
netupitant
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
OGX-427
olaparib
olaratumab
onartuzumab
Onyvax-105
oregovomab
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
perifosine
pertuzumab
PF-4856884
plitidepsin
PLX-3397
polyclonal antibody stimulator
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
Reditux
retaspimycin
RG-7160
ridaforolimus
rilotumumab
rindopepimut
rituximab
robatumumab
romidepsin
romiplostim
romurtide
ruxolitinib
sagopilone
samalizumab
SAR-3419
sargramostim
SB-939
siltuximab
sipuleucel-T
sorafenib tosylate
sotatercept
Survivac
Sym-004
TAK-448
tandutinib
tasquinimod
temsirolimus
Tenarad
thymalfasin
tigatuzumab
TM-30339
tocilizumab
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
vapreotide, immediate-release
veltuzumab
vitespen
volociximab
VX-001
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Antibodies and Peptides.
    To find out more about Triple Analysis: Prostate Cancer, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Prostate Cancer. Learn More


Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More


Triple Analysis: Lung Cancer, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Antibodies. Learn More